

Chapter 73

Albinism and Other Genetic Disorders of Pigmentation

Thomas J. Hornyak

REFERENCES

1. Witkop CJ Jr: Albinism. *Clin Dermatol* 7:80-91, 1989
2. Witkop CJ Jr: Inherited disorders of pigmentation. *Clin Dermatol* 3:70-134, 1985
3. King RA, Oetting WS: Oculocutaneous albinism. In: *The Pigmentary System: Physiology and Pathophysiology*, 2nd edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Massachusetts, Blackwell, 2006, pp. 599-612
4. Kromberg JG, Jenkins T: Prevalence of albinism in the South African negro. *S Afr Med J* 61:383-386, 1982
5. Spritz RA et al: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). *Am J Hum Genet* 56:1320-1323, 1995
6. Keeler C: The incidence of Cuna moon-child albinos. *J Hered* 55:115-120, 1964
7. Oetting WS et al: Oculocutaneous Albinism Type 1: The Last 100 Years. *Pigment Cell Res* 16:307-311, 2003. doi:10.1034/j.1600-0749.2003.00045.x
8. Suzuki T, Tomita Y: Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4. *J Dermatol Sci* 51:1-9, 2008
9. Wei ML: Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. *Pigment Cell Res* 19:19-42, 2006. doi:10.1111/j.1600-0749.2005.00289.x
10. Dourmishev AL et al: Waardenburg syndrome. *Int J Dermatol* 38:656-663, 1999. doi:10.1046/j.1365-4362.1999.00750.x
11. Nayak CS, Isaacson G: Worldwide distribution of Waardenburg syndrome. *Ann Otol Rhinol Laryngol* 112:817-820, 2003
12. Creel D et al: Auditory brainstem anomalies in human albinos. *Science* 209:1253-1255, 1980
13. Lund RD: Uncrossed visual pathways of hooded and albino rats. *Science* 149:1506-1507, 1965
14. Gimenez E et al: A transgenic mouse model with inducible Tyrosinase gene expression using the tetracycline (Tet-on) system allows regulated rescue of abnormal chiasmatic projections found in albinism. *Pigment Cell Res* 17:363-370, 2004
15. Lavado A et al: Ectopic expression of tyrosine hydroxylase in the pigmented epithelium rescues the retinal abnormalities and visual function common in albinos in the absence of melanin. *J Neurochem* 96:1201-1211, 2006
16. Summers C: Albinism: Classification, clinical characteristics, and recent findings. *Optom Vis Sci* 86:659-662, 2009
17. Tomita Y et al: Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene. *Biochem Biophys Res Commun* 164:990-996, 1989
18. Spritz RA et al: Detection of mutations in the tyrosinase gene in a patient with type IA oculocutaneous albinism. *N Engl J Med* 322:1724-1728, 1990
19. Giebel LB et al: A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism. *Proc Natl Acad Sci USA* 87:3255-3258, 1990
20. Hutton SM, Spritz RA: Comprehensive analysis of oculocutaneous albinism among non-hispanic caucasians shows that OCA1 is the most prevalent OCA type. *J Invest Dermatol* 128:2442-2450, 2008
21. King RA, Oetting WS: Molecular basis of type IA (tyrosinase negative) oculocutaneous albinism. *Pigment Cell Res* 5(Suppl. 2):249-253, 1992
22. Park HY et al: Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. *J Biol Chem* 274:16470-16478, 1999
23. Oetting WS, Fryer JP, King RA: Mutations of the human tyrosinase gene associated with tyrosinase related oculocutaneous albinism (OCA1). *Hum Mutat* 12:433-434, 1998
24. Tripathi RK et al: Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions. *Am J Med Genet* 43:865-871, 1992

25. Chintamaneni C et al: A single base insertion in the putative transmembrane domain of the tyrosinase gene as a cause for tyrosinase-negative oculocutaneous albinism. *Proc Natl Acad Sci USA* **88**:5272-5276, 1991.10.1073/pnas.88.12.5272.
26. Giebel LB et al: Tyrosinase gene mutations associated with type IB ("yellow") oculocutaneous albinism. *Am J Hum Genet* **48**:1159-1167, 1991
27. King RA et al: Temperature-sensitive tyrosinase associated with peripheral pigmentation in oculocutaneous albinism. *J Clin Invest* **87**:1046-1053, 1991
28. Berson JF et al: A common temperature-sensitive allelic form of human tyrosinase is retained in the endoplasmic reticulum at the nonpermissive temperature. *J Biol Chem* **275**:12281-12289, 2000
29. Halaban R et al: Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. *Proc Natl Acad Sci USA* **97**:5889-5894, 2000
30. Toyofuku K et al: Oculocutaneous albinism types 1 and 3 are ER retention diseases: Mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. *Faseb J* **15**:2149-2161, 2001
31. Kwon BS, Halaban R, Chintamaneni C: Molecular basis of mouse Himalayan mutation. *Biochem Biophys Res Commun* **161**:252-260, 1989
32. Lyons LA et al: Tyrosinase mutations associated with Siamese and Burmese patterns in the domestic cat (*Felis catus*). *Anim Genet* **36**:119-126, 2005
33. Rinchik EM et al: A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. *Nature* **361**:72-76, 1993
34. Woolf CM: Albinism (OCA2) in amerindians. *Am J Phys Anthropol* **128**:118-140, 2005
35. Lee ST et al: Organization and sequence of the human P gene and identification of a new family of transport proteins. *Genomics* **26**:354-363, 1995
36. Rosembat S et al: Identification of a melanosomal membrane protein encoded by the pink-eyed dilution (type II oculocutaneous albinism) gene. *Proc Natl Acad Sci USA* **91**:12071-12075, 1994
37. Lee S-T et al: Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. *N Engl J Med* **330**:529-534, 1994.10.1056/NEJM199402243300803
38. Durham-Pierre D et al: African origin of an intragenic deletion of the human P gene in tyrosinase positive oculocutaneous albinism. *Nat Genet* **7**:176-179, 1994
39. Durham-Pierre D et al: Estimation of carrier frequency of a 2.7 kb deletion allele of the P gene associated with OCA2 in African-Americans. *Hum Mutat* **7**:370-373, 1996
40. Stevens G et al: An intragenic deletion of the P gene is the common mutation causing tyrosinase-positive oculocutaneous albinism in southern African Negroids. *Am J Hum Genet* **56**:586-591, 1995
41. Puri N et al: Type 2 oculocutaneous albinism (OCA2) in Zimbabwe and Cameroon: Distribution of the 2.7-kb deletion allele of the P gene. *Hum Genet* **100**:651-656, 1997
42. Lund PM et al: Oculocutaneous albinism in an isolated Tonga community in Zimbabwe. *J Med Genet* **34**:733-735, 1997
43. Stevens G, Ramsay M, Jenkins T: Oculocutaneous albinism (OCA2) in sub-Saharan Africa: Distribution of the common 2.7-kb P gene deletion mutation. *Hum Genet* **99**:523-527, 1997
44. Kerr R et al: Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. *Hum Mutat* **15**:166-172, 2000
45. Witkop CJ Jr et al: Medical and dental findings in the Brandywine isolate. *Ala J Med Sci* **3**:382-403, 1966
46. Witkop CJ Jr et al: Tyrosinase positive oculocutaneous albinism among the Zuni and the Brandywine triracial isolate: Biochemical and clinical characteristics and fertility. *Am J Phys Anthropol* **36**:397-405, 1972
47. Brilliant MH: The mouse p (pink-eyed dilution) and human P genes, oculocutaneous albinism type 2 (OCA2), and melanosomal pH. *Pigment Cell Res* **14**:86-93, 2001
48. Yi Z et al: A 122.5-kilobase deletion of the P gene underlies the high prevalence of oculocutaneous albinism type 2 in the Navajo population. *Am J Hum Genet* **72**:62-72, 2003
49. Carrasco A et al: A splice site mutation is the cause of the high prevalence of oculocutaneous albinism type 2 in the Kuna population. *Pigment Cell Melanoma Res* **22**:645-647, 2009
50. Puri N, Gardner JM, Brilliant MH: Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. *J Invest Dermatol* **115**:607-613, 2000
51. Brilliant M, Gardner J: Melanosomal pH, pink locus protein and their roles in melanogenesis. *J Invest Dermatol* **117**:386-387, 2001
52. Duffy DL et al: A Three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most human eye-color variation. *Am J Hum Genet* **80**:241-252, 2007

53. Azzato EM et al: Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. *J Natl Cancer Inst* **102**:650-662, 2010
54. Staleva L, Manga P, Orlow S: Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. *Mol Biol Cell* **13**:4206-4220, 2002
55. Kromberg JG et al: Albinism and skin cancer in Southern Africa. *Clin Genet* **36**:43-52, 1989
56. King RA et al: Hypopigmentation in Angelman syndrome. *Am J Med Genet* **46**:40-44, 1993
57. Wiesner GL et al: Hypopigmentation in the Prader-Willi syndrome. *Am J Hum Genet* **40**:431-442, 1987
58. Hamabe J et al: DNA deletion and its parental origin in Angelman syndrome patients. *Am J Med Genet* **41**:64-68, 1991
59. Hamabe J et al: Molecular study of the Prader-Willi syndrome: Deletion, RFLP, and phenotype analyses of 50 patients. *Am J Med Genet* **41**:54-63, 1991
60. Boissy RE et al: Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: A new subtype of albinism classified as "OCA3". *Am J Hum Genet* **58**:1145-1156, 1996
61. Manga P et al: Rufous oculocutaneous albinism in southern African Blacks is caused by mutations in the TYRP1 gene. *Am J Hum Genet* **61**:1095-1101, 1997
62. Forshew T et al: Identification of novel TYR and TYRP1 mutations in oculocutaneous albinism. *Clin Genet* **68**:182-184, 2005. doi:10.1111/j.1399-0004.2005.00460.x
63. Rooryck C et al: Oculocutaneous albinism with TYRP1 gene mutations in a Caucasian patient. *Pigment Cell Res* **19**:239-242, 2006. doi:10.1111/j.1600-0749.2006.00298.x
64. Chiang P-W et al: Synergistic interaction of the OCA2 and OCA3 genes in a family. *Am J Med Genet A* **146A**:2427-2430, 2008
65. Kobayashi T et al: Tyrosinase stabilization by Tyrp1 (the brown locus protein). *J Biol Chem* **273**:31801-31805, 1998
66. Newton JM et al: Mutations in the human orthologue of the mouse underwhite gene (*uw*) underlie a new form of oculocutaneous albinism, OCA4. *Am J Hum Genet* **69**:981-988, 2001
67. Inagaki K et al: Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. *Am J Hum Genet* **74**:466-471, 2004
68. Fukumachi S, Shimada A, Shima A: Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka. *Nat Genet* **28**:381-385, 2001
69. Gunay-Aygun M, Huizing M, Gahl WA: Molecular defects that affect platelet dense granules. *Semin Thromb Hemost* **30**:537-547, 2004
70. Huizing M, Gahl WA: Disorders of vesicles of lysosomal lineage: The Hermansky-Pudlak syndromes. *Curr Mol Med* **2**:451-467, 2002
71. Anderson PD et al: Hermansky-Pudlak syndrome type 4 (HPS-4): Clinical and molecular characteristics. *Hum Genet* **113**:10-17, 2003
72. Anikster Y et al: Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. *Nat Genet* **28**:376-380, 2001
73. Huizing M et al: Hermansky-Pudlak syndrome type 3 in Ashkenazi Jews and other non-Puerto Rican patients with hypopigmentation and platelet storage-pool deficiency. *Am J Hum Genet* **69**:1022-1032, 2001
74. Tsilou ET et al: Milder ocular findings in Hermansky-Pudlak syndrome type 3 compared with Hermansky-Pudlak syndrome type 1. *Ophthalmology* **111**:1599-1603, 2004
75. Gahl WA et al: Genetic Defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak Syndrome). *N Engl J Med* **338**(18):1258-1265, 1998
76. Wei ML: Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. *Pigment Cell Res* **19**:19-42, 2006
77. Vincent LM et al: Hermansky-Pudlak syndrome type 1 in patients of Indian descent. *Mol Genet Metab* **97**:227-233, 2009
78. Wei A et al: The first case report of a Chinese Hermansky-Pudlak syndrome patient with a novel mutation on HPS1 gene. *J Dermatol Sci* **56**:130-132, 2009
79. Gahl WA et al: Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak Syndrome). *N Engl J Med* **338**:1258-1265, 1998. doi:10.1056/NEJM199804303381803
80. Oh J et al: Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. *Nat Genet* **14**:300-306, 1996

81. Dell'Angelica EC et al: Molecular characterization of the protein encoded by the Hermansky-Pudlak syndrome type 1 gene. *J Biol Chem* **275**:1300-1306, 2000
82. Chiang PW et al: The Hermansky-Pudlak syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles. *J Biol Chem* **278**:20332-20337, 2003
83. Martina JA, Moriyama K, Bonifacino JS: BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. *J Biol Chem* **278**:29376-29384, 2003
84. Nazarian R, Falcon-Perez JM, Dell'Angelica EC: Biogenesis of lysosome-related organelles complex 3 (BLOC-3): A complex containing the Hermansky-Pudlak syndrome (HPS) proteins HPS1 and HPS4. *Proc Natl Acad Sci USA* **100**:8770-8775, 2003
85. Richmond B et al: Melanocytes derived from patients with Hermansky-Pudlak Syndrome types 1, 2, and 3 have distinct defects in cargo trafficking. *J Invest Dermatol* **124**:420-427, 2005
86. Boissy RE, Zhao Y, Gahl WA: Altered protein localization in melanocytes from Hermansky-Pudlak syndrome: Support for the role of the HPS gene product in intracellular trafficking. *Lab Invest* **78**:1037-1048, 1998
87. Jedlitschky G et al: The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. *Blood* **104**:3603-3610, 2004
88. Dell'Angelica EC et al: Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. *Mol Cell* **3**:11-21, 1999
89. Huizing M et al: AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. *Mol Biol Cell* **12**:2075-2085, 2001
90. Clark RH, Stinchcombe JC et al: Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. *Nat Immunol* **4**:1111-1120, 2003
91. Di Pietro SM et al: Characterization of BLOC-2, a complex containing the Hermansky-Pudlak syndrome proteins HPS3, HPS5 and HPS6. *Traffic* **5**(4):276-283, 2004
92. Gautam R et al: The Hermansky-pudlak syndrome 3 (Cocoa) protein is a component of the biogenesis of lysosome-related organelles complex-2 (BLOC-2). *J Biol Chem* **279**(13):12935-12942, 2004
93. Boissy RE et al: Melanocyte-specific proteins are aberrantly trafficked in melanocytes of Hermansky-Pudlak syndrome-type 3. *Am J Pathol* **166**:231-240, 2005
94. Huizing M et al: Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. *Annu Rev Genomics Hum Genet* **9**:359-386, 2008
95. Tomita Y, Suzuki T: Genetics of pigmentary disorders. *Am J Med Genet* **131C**:75-81, 2004
96. Introne W, Boissy RE, Gahl WA: Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. *Mol Genet Metab* **68**:283-303, 1999
97. Nagle DL et al: Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. *Nat Genet* **14**:307-311, 1996
98. Karim MA et al: Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. *Am J Med Genet* **108**:16-22, 2002
99. Valenzuela R, Morningstar WA: The ocular pigmentary disturbance of human Chediak-Higashi syndrome. A comparative light- and electron-microscopic study and review of the literature. *Am J Clin Pathol* **75**:591-596, 1981
100. Zhao H et al: On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes. *Lab Invest* **71**:25-34, 1994
101. de Beer HA, Anderson R, Findlay GH: Chediak-Higashi syndrome in a "Black" child. *S Afr Med J* **60**:108-112, 1981
102. Trambas CM, Griffiths GM: Delivering the kiss of death. *Nat Immunol* **4**:399-403, 2003
103. Barrat FJ et al: Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: A possible mechanism for deregulation of T lymphocyte activation. *Proc Natl Acad Sci USA* **96**:8645-8650, 1999
104. Waardenburg PJ: A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. *Am J Hum Genet* **3**:195-253, 1951
105. Baldwin CT et al: An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. *Nature* **355**:637-638, 1992
106. Tassabehji M et al: Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. *Nature* **355**:635-636, 1992

107. Tassabehji M, Newton VE, Read AP: Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. *Nat Genet* **8**:251-255, 1994
108. Hughes AE et al: A gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1. *Nat Genet* **7**:509-512, 1994
109. Hoth CF et al: Mutations in the paired domain of the human PAX3 gene cause Klein-Waardenburg syndrome (WS-III) as well as Waardenburg syndrome Type I (WS-I). *Am J Hum Genet* **52**:455-462, 1993
110. Pasteris NG et al: Discordant phenotype of two overlapping deletions involving the PAX3 gene in chromosome 2q35. *Hum Mol Genet* **2**:953-959, 1993
111. Edery P et al: Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). *Nat Genet* **12**:442-444, 1996
112. Bidaud C et al: Endothelin-3 gene mutations in isolated and syndromic Hirschsprung disease. *Eur J Hum Genet* **5**:247-251, 1997
113. Hofstra RM et al: A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). *Nat Genet* **12**:445-447, 1996
114. Puffenberger EG et al: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. *Cell* **79**:1257-1266, 1994
115. Pingault V et al: SOX10 mutations in patients with Waardenburg-Hirschsprung disease. *Nat Genet* **18**:171-173, 1998
116. Read AP, Newton VE: Waardenburg syndrome. *J Med Genet* **34**:656-665, 1997
117. Liu XZ, Newton VE, Read AP: Waardenburg syndrome type II: Phenotypic findings and diagnostic criteria. *Am J Med Genet* **55**:95-100, 1995
118. Potterf B, Arnheiter H, Pavan WJ: Transcription factor hierarchy in Waardenburg syndrome: Regulation of MITF expression by SOX10 and PAX3. *Hum Genet* **107**:1-6, 2000
119. Bondurand N et al: Interaction among SOX10, PAX3, and MITF, three genes altered in Waardenburg syndrome. *Hum Mol Genet* **9**:1907-1917, 2000
120. Helms JA, Schneider RA: Cranial skeletal biology. *Nature* **423**:326-331, 2003
121. Merchant SN et al: Otopathology in a case of type I Waardenburg's syndrome. *Ann Otol Rhinol Laryngol* **110**:875-882, 2001
122. Takasaki K, Balaban CD, Sando I: Histopathologic findings of the inner ears with Alport, Usher and Waardenburg syndromes. *Adv Otorhinolaryngol* **56**:218-232, 2000
123. Tassabehji M et al: The mutational spectrum in Waardenburg syndrome. *Hum Mol Genet* **4**:2131-2137, 1995
124. Sanchez-Martin M et al: SLUG (SNAI2) deletions in patients with Waardenburg disease. *Hum Mol Genet* **11**:3231-3236, 2002
125. Bondurand N et al: Deletions at the SOX10 Gene Locus Cause Waardenburg Syndrome Types 2 and 4. *Am J Hum Genet* **81**:1169-1185, 2007
126. Hemesath TJ et al: *microphthalmia*, a critical factor in melanocyte development, defines a discrete transcription factor family. *Genes Dev* **8**:2770-2780, 1994
127. Pingault V et al: Review and update of mutations causing waardenburg syndrome. *Hum Mutat* **31**:391-406, 2010
128. Maroto M et al: Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. *Cell* **89**:139-148, 1997
129. Verheji J, Hofstra RMW, EDNRB, EDN3, and SOX10 and the Shah-Waardenburg syndrome. In: *Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis*, edited by CJ Epstein, RP Erickson, A Wynshaw-Boris. New York, Oxford University Press, 2004, pp. 440-446
130. Tietz W: A syndrome of deaf-mutism associated with albinism showing dominant autosomal inheritance. *Am J Hum Genet* **15**:259-264, 1963
131. Amiel J et al: Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome). *Clin Dysmorphol* **7**:17-20, 1998
132. Izumi K et al: Tietz syndrome: Unique phenotype specific to mutations of MITF nuclear localization signal. *Clin Genet* **74**:93-95, 2008
133. Hodgkinson CA et al: Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. *Cell* **74**:395-404, 1993
134. Hornyak TJ et al: Transcription factors in melanocyte development: Distinct roles for Pax-3 and Mitf. *Mech Dev* **101**:47-59, 2001
135. Smith SD et al: Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. *J Med Genet* **37**:446-448, 2000

136. Steingrimsdottir E, Copeland NG, Jenkins NA: Melanocytes and the microphthalmia transcription factor network. *Annu Rev Genet* **38**:365-411, 2004
137. Schwarzbraun T et al: A new 3p interstitial deletion including the entire *MITF* gene causes a variation of Tietz/Waardenburg type IIA syndromes. *Am J Med Genet A* **143A**:619-624, 2007
138. Giebel LB, Spritz RA: Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. *Proc Natl Acad Sci US A* **88**:8696-8699, 1991
139. Hemesath TJ et al: MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. *Nature* **391**:298-301, 1998
140. Spritz RA, Beighton P: Piebaldism with deafness: Molecular evidence for an expanded syndrome. *Am J Med Genet* **75**:101-103, 1998
141. Miyamura Y et al: Mutations of the RNA-specific adenosine deaminase gene (*DSRAD*) are involved in dyschromatosis symmetrica hereditaria. *Am J Hum Genet* **73**:693-699, 2003
142. Murata I et al: Mutation analyses of patients with dyschromatosis symmetrica hereditaria: Five novel mutations of the *ADAR1* gene. *J Dermatol Sci* **58**(3):218-220, 2010
143. Filipovich AH: Hemophagocytic lymphohistiocytosis and related disorders. *Curr Opin Allergy Clin Immunol* **6**:410-415, 2006
144. Gupta S, Kumar B: Epidermal grafting in vitiligo: Influence of age, site of lesion, and type of disease on outcome. *J Am Acad Dermatol* **49**:99-104, 2003
145. Grimes PE: New insights and new therapies in vitiligo. *JAMA* **293**:730-735, 2005.10.1001/jama.293.6.730
146. van Geel N et al: Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. *Arch Dermatol* **140**:1203-1208, 2004.10.1001/archderm.140.10.1203
147. Cullen RD et al: Cochlear implants in Waardenburg syndrome. *Laryngoscope* **116**:1273-1275, 2006
148. King RA et al: Albinism in Nigeria with delineation of new recessive oculocutaneous type. *Clin Genet* **17**:259-70, 1980.
149. King RA. Albinism. In: *The Pigmentary System: Physiology and Pathophysiology*, 1st edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, J-P Ortonne. New York, Oxford University Press, 1998, pp. 553-574
150. Saitoh S et al: Oculocutaneous albinism type 2 with a P gene missense mutation in a patient with Angelman syndrome. *J Med Genet* **37**:392-394, 2000
151. Bahadoran P, Ortonne J-P: Albinoid Disorders. In: *The Pigmentary System: Physiology and Pathophysiology*, 2nd edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 613-621
152. Boissy RE et al: Human tyrosinase related protein-1 (TRP-1) does not function as a DHICA oxidase activity in contrast to murine TRP-1. *Exp Dermatol* **7**:198-204, 1998
153. Kobayashi T et al: Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. *Embo J* **13**:5818-5825, 1994
154. Huizing M et al: Nonsense mutations in *ADTB3A* cause complete deficiency of the β 3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. *Pediatr Res* **51**(2):150-158, 2002
155. Jung J et al: Identification of a homozygous deletion in the *AP3B1* gene causing Hermansky-Pudlak syndrome, type 2. *Blood* **108**(1):362-369, 2006
156. Wenham M et al: Two patients with Hermansky-Pudlak syndrome type 2 and novel mutations in *AP3B1*. *Haematologica* **95**:333-337, 2010
157. Huizing M et al: Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. *Traffic* **5**(9):711-722, 2004
158. Zhang Q et al: *Ru2* and *Ru* encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. *Nat Genet* **33**:145-153, 2003
159. Korswagen L-A et al: A novel mutation in a Turkish patient with Hermansky-Pudlak syndrome type 5. *Eur J Haematol* **80**:356-360, 2008
160. Schreyer-Shafir N et al: A new genetic isolate with a unique phenotype of syndromic oculocutaneous albinism: Clinical, molecular, and cellular characteristics. *Hum Mutat* **27**:1158, 2006
161. Li W et al: Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). *Nat Genet* **35**:84-89, 2003
162. Morgan NV et al: A germline mutation in *BLOC1S3/reduced pigmentation* causes a novel variant of Hermansky-Pudlak syndrome (HPS8). *Am J Hum Genet* **78**:160-166, 2006

163. Huizing M et al: Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. *Traffic* 5:711-722, 2004, doi:10.1111/j.1600-0854.2004.00208.x
164. Zhang Q et al: Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. *33*:145-153, 2003
165. Li W et al: Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). *35*:84-89, 2003
166. Benson MA et al: Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. 24232-24241, 2001
167. Sadoulet-Puccio HM, Rajala M, Kunkel LM: Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. 12413-12418, 1997
168. Nazarian R et al: Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein. *Biochem J* 395:587-598, 2006
169. Gwynn B et al: Reduced pigmentation (rp), a mouse model of Hermansky-Pudlak syndrome, encodes a novel component of the BLOC-1 complex. *Blood* 104:3181-3189, 2004
170. Starcevic M, Dell'Angelica EC: Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1). *J Biol Chem* 279:28393-283401, 2004
171. Reed WB et al: Hereditary syndromes with auditory and dermatological manifestations. *Arch Dermatol* 95:456-461, 1967
172. Reed WB et al: Pigmentary disorders in association with congenital deafness. *Arch Dermatol* 95:176-186, 1967
173. Spritz RA: Genetic hypomelanoses: Disorders characterized by congenital white spotting-piebaldism, waardenburg syndrome, and related genetic disorders of melanocyte development-clinical aspects. In: *The Pigmentary System: Physiology and Pathophysiology*. 2nd edition, edited by, JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 541-550
174. Cross HE, McKusick VA, Breen W: A new oculocerebral syndrome with hypopigmentation. *J Pediatr* 70:398-406, 1967
175. Bolognia JL: Oculocerebral syndrome with hypopigmentation. In: *The Pigmentary System: Physiology and Pathophysiology*. 2nd edition, JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 626-630

